One immunodeficiency affects cytosolic Mg2+ levels, required for PLCγ1 activation, via mutations in the magnesium transporter 1 (MAGT1) in patients with X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia (XMEN) [47–51]. Here, PLCG1 is linked to neoplasm.